AZD 0284

Drug Profile

AZD 0284

Alternative Names: AZD0284

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AstraZeneca
  • Class Antipsoriatics; Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Plaque psoriasis; Respiratory tract disorders

Most Recent Events

  • 16 Oct 2017 AstraZeneca plans the phase Ib DERMIS trial for Plaque psoriasis in Denmark (PO, Liquid) (NCT03310320)
  • 06 Jul 2017 Phase-I clinical trials in Respiratory tract disorders (PO) in United Kingdom (AstraZeneca pipeline, July 2017)
  • 25 Apr 2017 AstraZeneca completes a phase I trial in Plaque psoriasis (In volunteers) in United Kingdom (PO and IV) (NCT03029741)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top